Printer Friendly

CARDIOPULMONICS ANNOUNCES CHANGES IN SENIOR MANAGEMENT; INTERIM CHIEF EXECUTIVE OFFICER NAMED; NEW BOARD MEMBERS ADDED

 SALT LAKE CITY, Jan. 20 /PRNewswire/ -- CardioPulmonics Inc. (NASDAQ: CRDS) announced today that George M. Sims, the company's president and chief executive officer, has resigned. Sims has informed the board of directors that his need to assist a family member in prolonged recuperation from recent cardiac surgeries will prevent him from providing day to day management of the company. Sims will continue to serve on the board of directors and will assist the company as his family responsibilities permit.
 In view of Sims' resignation, the board of directors has initiated a search for his replacement and announces the appointment of Herbert G. Taus as the full-time chief executive officer until the search for his replacement has been filled. Since October 1991, Taus has been a principal with Medical Device Consultan. Taus has more than 35 years of experience in the medical device industry, including marketing, engineering and general management positions with General Electric, Abbott Laboratories and Medtronic Inc. Additionally, Taus has been appointed to the CardioPulmonics' board of directors.
 The company also announced the recent appointment of Robert M. Curtis as a director of the company. Curtis is currently president and chief operating officer of Health Devices Research Institute, a firm specializing in the tracking and post-market surveillance of medical devices. He also provides international business development and management services to several medical device companies. Curtis is the former president of Urosystems Inc. and prior to that was president of Shiley Inc. and a senior vice president of Pfizer Hospital Products Group. Curtis has extensive experience in the cardiopulmonary and cardiovascular device markets.
 CardioPulmonics Inc., manufacturers the IVOX(R) device (Intravascular Oxygenator) under an IDE (Investigational Device Exemption) from the FDA (United States Food and Drug Administration).
 -0- 1/20/93
 /CONTACT: William S. Barth of CardioPulmonics, 801-350-3651/
 (CRDS)


CO: CardioPulmonics Inc. ST: Utah IN: MTC SU: PER

BP -- LA024 -- 6903 01/20/93 12:59 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jan 20, 1993
Words:317
Previous Article:FLANIGAN'S ENTERPRISES, INC. ANNOUNCES RESULTS
Next Article:LAKEHEAD PIPE LINE PARTNERS L.P. ANNOUNCES FOURTH QUARTER 1992 FINANCIAL RESULTS
Topics:


Related Articles
PARK-OHIO NAMES McGINTY INTERIM CHAIRMAN AND CEO; KIRKHOFF AS INTERIM VICE CHAIRMAN
BURRITT ANNOUNCES MANAGEMENT CHANGES
CARDIOPULMONICS ANNOUNCES DISCUSSION WITH FDA OF PMA SUBMISSION OF IVOX DEVICE
CARDIOPULMONICS ANNOUNCES APPOINTMENT OF NEW PRESIDENT AND CEO
CARDIOPULMONICS, INC. SIGNS DEFINITIVE AGREEMENT TO ACQUIRE INNERDYNE MEDICAL, INC.
CARDIOPULMONICS INC. SIGNS AGREEMENT TO LICENSE COATING TECHNOLOGY TO SENKO MEDICAL INSTRUMENT MANUFACTURING CO. LTD., TOKYO
CARDIOPULMONICS INC. AND INNERDYNE MEDICAL ANNOUNCE APPROVAL OF MERGER
INNERDYNE INC. ANNOUNCES THE ESTABLISHMENT OF A NEW COMPANY TO PURSUE RESEARCH AND DEVELOPMENT OF GAS EXCHANGE AND BLOOD PUMPING TECHNOLOGIES
FoxHollow Technologies Announces Management Transition.
Bristol-Myers Squibb Board of Directors Announces Departure of Peter R. Dolan as CEO and Appointment of James M. Cornelius as Interim CEO.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters